U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H19FN3O4.Na
Molecular Weight 383.3493
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOFLOXACIN SODIUM

SMILES

[Na+].C[C@H]1COC2=C3N1C=C(C([O-])=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4

InChI

InChIKey=NCGMIBYQHQSCGQ-PPHPATTJSA-M
InChI=1S/C18H20FN3O4.Na/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h7-8,10H,3-6,9H2,1-2H3,(H,24,25);/q;+1/p-1/t10-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C18H19FN3O4
Molecular Weight 360.3596
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.

CNS Activity

Curator's Comment: levofloxacin penetrates the cerebrospinal fluid (CSF) during meningeal inflammation both in animals and in humans

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

1996
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

1996
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

1996
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

1996
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

1996
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.9 mg/L
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.8 mg/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
11.8 mg/L
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.85 mg/L
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.04 mg/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.3 mg/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
49.6 mg × h/L
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
59 mg × h/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
118 mg × h/L
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
111 mg × h/L
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
19.88 mg × h/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55.3 mg × h/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.6 h
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.4 h
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.9 h
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.9 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
5.97 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.6 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.4%)
Nausea (0.6%)
Vomiting (0.4%)
Dizziness (0.3%)
Headache (0.2%)
Sources: Page: 19
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.4%)
Nausea (0.6%)
Vomiting (0.4%)
Dizziness (0.3%)
Headache (0.2%)
Sources: Page: 19
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.2%)
Nausea (0.6%)
Vomiting (0.5%)
Dizziness (0.3%)
Headache (0.3%)
Sources: Page: 19
AEs

AEs

AESignificanceDosePopulation
Headache 0.2%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Dizziness 0.3%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Vomiting 0.4%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Nausea 0.6%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Gastrointestinal disorder 1.4%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Headache 0.2%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Dizziness 0.3%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Vomiting 0.4%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Nausea 0.6%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Gastrointestinal disorder 1.4%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Dizziness 0.3%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Headache 0.3%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Vomiting 0.5%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Nausea 0.6%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Gastrointestinal disorder 1.2%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
yes [Km 136 uM]
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
1999 Jul
Levofloxacin.
1999 Nov
Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
1999 Oct
Antimycobacterial activities of novel levofloxacin analogues.
2000 Aug
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.
2000 Oct
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.
2000 Oct
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
2000 Sep
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
2001
In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.
2001 Apr
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
2001 Apr
In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
2001 Apr
Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.
2001 Feb
Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients.
2001 Feb
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study.
2001 Feb
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.
2001 Feb 15
[In vitro antimycobacterial activities of a new quinolone, balofloxacin].
2001 Jan
Community-acquired pneumonia. Diagnostic and therapeutic approach.
2001 Jan
In vitro and in vivo antimicrobial activity of topical ofloxacin and other ototopical agents.
2001 Jan
In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae.
2001 Jan
Measurement of the bactericidal activity of fluoroquinolones against Streptococcus pneumoniae using the bactericidal index method.
2001 Jan
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
2001 Jul
Complicated urinary tract infections in patients with voiding dysfunction.
2001 Jun
Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy.
2001 Jun
Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece.
2001 Jun
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
2001 Jun
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
2001 Jun
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
2001 Mar
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.
2001 Mar
Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.
2001 Mar
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
2001 Mar 12
In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.
2001 Mar-Apr
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.
2001 May
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.
2001 May
An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum.
2001 May
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.
2001 May 15
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.
2001 May-Jun
Patents

Sample Use Guides

The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours. Nosocomial Pneumonia: 750 mg during 7–14 days Community Acquired Pneumonia: 500 mg during 7–14 days Community Acquired Pneumonia§ 750 mg during 5 days Complicated Skin and Skin Structure Infections (SSSI) 750 mg during 7–14 days Uncomplicated SSSI 500 mg during 7–10 days Chronic Bacterial Prostatitis 500 mg during 28 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 750 mg during 5 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 250 mg during 10 days Uncomplicated Urinary Tract Infection 250 mg 3 during days Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg during 7 days Acute Bacterial Sinusitis (ABS) 750 mg days or 500 mg during 10–14 days.
Route of Administration: Other
In Vitro Use Guide
Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:18:41 GMT 2023
Edited
by admin
on Fri Dec 15 16:18:41 GMT 2023
Record UNII
1NF639GZUU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVOFLOXACIN SODIUM
WHO-DD  
Common Name English
Levofloxacin sodium [WHO-DD]
Common Name English
7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, SODIUM SALT, (3S)-
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID60236242
Created by admin on Fri Dec 15 16:18:41 GMT 2023 , Edited by admin on Fri Dec 15 16:18:41 GMT 2023
PRIMARY
SMS_ID
100000170514
Created by admin on Fri Dec 15 16:18:41 GMT 2023 , Edited by admin on Fri Dec 15 16:18:41 GMT 2023
PRIMARY
PUBCHEM
71300639
Created by admin on Fri Dec 15 16:18:41 GMT 2023 , Edited by admin on Fri Dec 15 16:18:41 GMT 2023
PRIMARY
CAS
872606-49-0
Created by admin on Fri Dec 15 16:18:41 GMT 2023 , Edited by admin on Fri Dec 15 16:18:41 GMT 2023
PRIMARY
EVMPD
SUB184489
Created by admin on Fri Dec 15 16:18:41 GMT 2023 , Edited by admin on Fri Dec 15 16:18:41 GMT 2023
PRIMARY
FDA UNII
1NF639GZUU
Created by admin on Fri Dec 15 16:18:41 GMT 2023 , Edited by admin on Fri Dec 15 16:18:41 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY